CASE CCC IN THE NEWS
Blood Test for Pancreatic Cancer Shows Promise in Early Trial
US News - Oct 25, 2013
Pancreatic cancer is one of the most lethal tumor types because it's too often diagnosed in a later, advanced stage. But a new study suggests that a simple blood test might help spot the disease earlier...Case Comprehensive Cancer Center member Dr. Smitha Krishnamurthi is an associate professor of medicine in the division of hematology and oncology with University Hospitals Case Medical Center & Case Western Reserve University School of Medicine, in Cleveland. She applauded the research, saying that "if pancreatic cancer could be detected at an early stage, more patients would be cured."
Experts Propose Ways to Boost Enrollment in Cancer Trials
Medscape - Oct 25, 2013
The National Cancer Institute (NCI) and the American Society of Clinical Oncology (ASCO) have joined forces to develop recommendations aimed at increasing the participation of cancer patients in clinical trials. "Participation in clinical trials is the best option for care in many instances, and should be available for all cancer patients," said Neal J. Meropol, MD, Associate Director for Clinical Research at the Case Comprehensive Cancer Center, and chief of the division of hematology and oncology at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine in Cleveland.
Government Shutdown Over, but Sequestration's Toll Now Taking Effect
ideastream - Oct 23, 2013
As Congress steps back to the negotiating table to work out the nation's budget, a key question between the parties will be whether the automatic spending cuts called sequestration should stay in place. There are those in Cleveland who are watching the debate closely...Behind the scenes, though, distractions are very real to people like Dr. Stan Gerson, whose office is just inside one of the older brick buildings. As director of the Case Comprehensive Cancer Center, Gerson spent much of the past year calling members of Congress and asking his staff to do the same.
Phase II Study Supports Axitinib Dose Titration in Select Treatment-Naive Metastatic Renal Cell Carcinoma Patients
ASCO Post - Oct 23, 2013
Axitinib plasma exposure may correlate with efficacy in metastatic renal cell carcinoma, according to population pharmacokinetic data. In a phase II study reported in The Lancet Oncology, Brian I. Rini, MD, of the Cleveland Clinic and Case Comprehensive Cancer Center, and colleagues evaluated the effects of axitinib dose titration in patients with previously untreated metastatic renal cell carcinoma. They found a higher response rate in patients receiving dose titration.
Obesity Before Pancreatic Cancer Shortens Survival
Medscape - Oct 21, 2013
Patients with pancreatic cancer who were obese in the years before their diagnosis have reduced survival, according to research published online today in the Journal of Clinical Oncology..."While previous retrospective studies suggested a link between obesity and pancreatic cancer survival, the prospective nature of this study makes the findings more reliable," said Smitha S. Krishnamurthi, MD, from the Case Comprehensive Cancer Center, Case Western Reserve University, and UH Seidman Cancer Center, in a press statement. She was not involved with the study, but offered her comments as a member of the Cancer Communications Committee at the American Society of Clinical Oncology.
Obesity and Cancer
WVIZ PBS - Oct 21, 2013
Most people know obesity can lead to heart attacks and diabetes, the connection between excess fat and certain cancers is a relatively new area of medical research. Watch the video to hear expert opinions from Case Comprehensive Cancer Center members Dr. Dale Shepard of the Cleveland Clinic and Drs. Kristine Zanotti and Amitabh Chak of University Hospitals Case Medical Center.
Case Western Reserve University School of Medicine Scientist Wins Prestigious NIH New Innovators Award
Newswise - Oct 21, 2013
Derek Taylor, PhD, a member of the Case Comprehensive Cancer Center and Assistant Professor of Pharmacology at Case Western Reserve University, has been awarded the prestigious New Innovator Award by the National Institutes of Health (NIH). The NIH awards this grant to scientists proposing highly innovative approaches to major contemporary challenges in biomedical research, under the agency's High Risk-High Reward program. "Only the absolute top notch scientists compete for this award, which undergoes intense review by leaders at the NIH," stated Stanton Gerson, MD, Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, director of the Case Comprehensive Cancer Center and director of the Seidman Cancer Center at UH Case Medical Center.
How Cancer Centers Are Coping with the Government Shutdown
Oncology Times - Oct 15, 2013
The government shutdown happened "right at the turn of the calendar, so new grant submissions are problematic," saidStan Gerson, MD, Director of the NCI-designated Case Comprehensive Cancer Center of Case Western University and University Hospitals Case Medical Center Seidman Cancer Center. "There's no feedback or engagement, so it has slowed down the review process."
Case Comprehensive Cancer Center Call for Applications
The Case Comprehensive Cancer Center has released the following pilot grant funding opportunities:
- Pilot Grants: Opportunities for Developing Patient-Derived Xenografts will support the development of patient-derived tumor xenografts (PDX) that will benefit collaborative, multi-investigator projects within the Cancer Center. This RFA is open to all Cancer Center members, regardless of institution.
Deadline: November 15
- Pilot Grants: Use of Tumor Genomic Evaluation for Clinical Decision-Making will provide seed money to foster collaborations and promote and increase institution-wide capacity and competitiveness in the use of tumor genomic evaluation for clinical decision-making. Case CCC members with faculty appointment at all levels (eligible to apply for independent nationally competitive research grants) are encouraged to apply. Proposals from both junior and senior investigators are encouraged. Research proposals must involve patients and/or their tissues.
Deadline: December 2
- Pilot Grants: Planning for Multi-Investigator Proposals will provide funding to further the important goal of facilitating successful applications for large multi-investigator grants (e.g., P01, P50, U54) in the current funding cycle. Applicants must demonstrate they are in communication with appropriate NIH administration, other structures within NIH, or other funding agencies (e.g., formal invitation, preparatory meeting, LOI and/or positive response to RFA or PA). Applicants must be Cancer Center members with faculty appointments, demonstrate intent to apply for national funding within a defined timeline, and describe new research that could not be achieved without the collaboration.
Ohio Brain Tumor SPORE Working Group
The Ohio Brain Tumor SPORE Working Group is accepting applications for the following opportunities:
- In preparation for an Ohio NIH P50 Brain Tumor SPORE Application, by CWRU, Case CCC, Cleveland Clinic and Nationwide Children's Hospital in Columbus, all faculty members at these institutions are invited to submit proposals for Ohio Brain Tumor SPORE Working Group Pilot Grants to be funded by the NIH and the Institutions. Note that a pilot SPORE project must be directed toward translational research relative to Brain Tumors.
Deadline: December 16
- The Ohio Brain Tumor SPORE Working Group and participating institutions including CWRU, Case CCC, Cleveland Clinic and Nationwide Children's Hospital in Columbus, will begin funding a new Career Development Scholars Training Program in the upcoming academic year, 2014-2015. This program is designed to support research training leading to independent careers in translational Brain Tumor research.
Deadline: December 23
AACR Basic Cancer Research Fellowships
The American Association for Cancer Research (AACR) Basic Cancer Research Fellowships are open to postdoctoral and clinical research fellows working at an academic, medical, or research institution who will be in the first, second, or third year of their postdoctoral training at the start of the grant term. The research proposed for funding may be in any area of basic cancer research.
LOI Deadline: October 30
A Survivorship Action Partnership – United States of America
The Movember Foundation and the Live Strong Foundation are partnering to to establish A Survivorship Action Partnership – United States of America (ASAP USA) as a collaborative network that will develop and implement an agreed set of interventions that together will have a strong likelihood of improving the lives of prostate cancer survivors in the United States. The focus of ASAP USA for the first three years will be interventions that can be implemented widely across the United States leveraging technology and telehealth. ASAP USA will have an agreed leadership and management structure and commit to knowledge sharing across the sector.
ASAP USA will be established through a two-step process. The first is a Request for Proposals inviting organizations and institutions with relevant experience in care and technology or telehealth to participate in ASAP USA. Selected members must understand and agree that they will be required to collaborate and work with a number of other selected members to design and implement ASAP interventions making up the Final Proposal.
In the second step selected members will be invited to form ASAP USA and develop a Final Proposal that details: a set of interventions in accordance with the ASAP requirements; and a leadership and management structure to implement the ASAP interventions. Movember will facilitate this process and provide appropriate funding to assist selected members collaboratively develop the Final Proposal. Annexure 2 details the process and criteria that will be used in relation to Final Proposal.
Deadline: November 13
International Association for the Study of Lung Cancer Fellowship and Young Investigators Programs
The International Association for the Study of Lung Cancer is proud to announce the annual IASLC Fellowship and Young Investigators Programs. The Prevent Cancer Foundation will jointly sponsor awards focused on lung cancer prevention and translational research, supported through educational grants from Eli Lilly. Additional unrestricted awards in any field of lung cancer research are supported by educational grants from Amgen, Genentech, Celgene, Merck KGaA, Eli Lilly, the IASLC and other sponsors. The goal is to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine.
Deadline: January 16, 2014
Radiological Society of North America
The Radiological Society of North America is accepting applications for the following funding opportunities:
- Research Seed Grants enable all levels of investigators throughout the world in defining objectives and testing hypotheses in preparation of major grant applications to corporations, foundations, and governmental agencies. The seed data from these projects will indicate feasibility and appropriateness of the research prior to applying for funds from other agencies.
Deadline: January 15, 2014
- Research Medical Student Grants increase the opportunities for medical students to have a research experience in medical imaging and to encourage them to consider academic radiology as an important option for their future. Recipients will gain experience in defining objectives, developing research skills and testing hypotheses before making their final choices for residency training programs. Students are expected to undertake a research project requiring full time efforts for at least 10 weeks under the guidance of a scientific advisor during personal/vacation time or during a research elective approved by their medical school.
Deadline: February 1, 2014